ABBOTT LABORATORIES (ABT) 97.355 +0.25 (+0.25%)
97.355 +0.25 (+0.25%)
US0028241000 - Common Stock
Fundamental Rating
Taking everything into account, ABT scores 5 out of 10 in our fundamental rating. ABT was compared to 220 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of ABT get a neutral evaluation. Nothing too spectacular is happening here. ABT is not valued too expensively and it also shows a decent growth rate.
Profitability
Profitability Rating
ABT's Return On Assets of 9.31% is amongst the best of the industry. ABT does better than the industry average Return On Assets of 5.24%.
ABT has a Return On Equity of 18.90%. This is better than the industry average of 9.03%.
ABT's Profit Margin of 15.88% is amongst the best of the industry. ABT does better than the industry average Profit Margin of 10.78%.
The Piotroski-F score of ABT is 6.00. This is a neutral score and indicates average health and profitability for ABT.
VS Industry
ROA (9.31%) VS Industry: 67% outperformed.
0.20
79.99
ROE (18.9%) VS Industry: 77% outperformed.
0.33
405.13
Profit Margin (15.88%) VS Industry: 70% outperformed.
0.35
867.21
Valuation
Valuation Rating
Compared to an average industry Price/Earning Ratio of 23.39, ABT is valued a bit cheaper than its industry peers.
When comparing the Enterprise Value to EBITDA ratio of ABT to the average industry ratio of 19.66, ABT is valued rather cheaply.
With a Price/Earnings Ratio of 18.23, ABT is valued on the expensive side.
The Forward Price/Earnings Ratio of 21.88 indicates a rather expensive current valuation of ABT.
The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
When comparing the current price to the book value of ABT, we can conclude it is valued correctly. It is trading at 4.61 times its book value.
When comparing the price book ratio of ABT to the average industry price book ratio of 2.65, ABT is valued more expensive than its industry peers.
VS Industry
Price/Earnings (18.23) VS Industry: 68% outperformed.
1,640.29
1.94
Price/Book (4.61) VS Industry: 28% outperformed.
66.28
0.07
Enterprise Value/ EBITDA (14.91) VS Industry: 64% outperformed.
336.82
2.41
Growth
Growth Rating
ABT shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 16.39% yearly.
ABT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.50%.
ABT is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 4.06% yearly.
ABT shows a small growth in Revenue. In the last year, the Revenue has grown by 1.34%.
ABT shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 9.77% yearly.
Based on estimates for the next 5 years, ABT will show a small growth in Revenue. The Revenue will grow by 3.03% on average per year.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 16.39% | 18.12% | 2.5% | -16.68% | -4.26% | 0.59% | 4.06% |
| Revenue | 9.77% | 11.02% | 1.34% | -7.36% | -1.22% | 1.28% | 3.03% |
Health
Health Rating
An Altman-Z score of 4.46 indicates that ABT is not in any danger for bankruptcy at the moment.
The Altman-Z score of ABT is much better than the industry average of 1.74.
A Current Ratio of 1.63 indicates that ABT should not have too much problems paying its short term obligations.
A Quick Ratio of 1.23 indicates that ABT should not have too much problems paying its short term obligations.
ABT has a Piotroski-F score of 6.00. This indicates an average health and profitability for ABT.
Compared to an average industry Current Ratio of 3.55, ABT is worse placed to pay its short term obligations than its industry peers. 82% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 2.77, ABT is worse placed to pay its short term obligations than its industry peers.
When comparing the Debt to Equity Ratio of ABT to the average industry Debt to Equity Ratio of 0.13, ABT required more debt to finance its operations than its industry peers.
VS Industry
Debt/Equity (0.4) VS Industry: 32% outperformed.
20.96
0.00
Quick Ratio (1.23) VS Industry: 23% outperformed.
0.06
25.78
Current Ratio (1.63) VS Industry: 18% outperformed.
0.12
25.78
Altman-Z (4.46) VS Industry: 75% outperformed.
-101.58
61.03
Dividend
Dividend Rating
ABT's Dividend Yield is a higher than the industry average which is at 1.25.
On average, the dividend of ABT grows each year by 13.67%, which is quite nice.
ABT has been paying a dividend for at least 10 years, so it has a reliable track record.
ABT has a Yearly Dividend Yield of 2.10%. Purely for dividend investing, there may be better candidates out there.
Compared to an average S&P500 Dividend Yield of 2.60, ABT has a dividend comparable with the average S&P500 company.
47.73% of the earnings are spent on dividend by ABT. This is a bit on the high side, but may be sustainable.
The Dividend Rate of ABT has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
VS Industry
Dividend Yield (2.1%) VS Industry: 73% outperformed.
0.02
5.70
ABBOTT LABORATORIES97.355
NYSE:ABT (3/29/2023, 11:27:02 AM)+0.25 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-25 2023-01-25/bmo
Earnings (Next)04-18 2023-04-18/bmo
Inst Owners76.76%
Inst Owner Change-56.47%
Ins Owners0.53%
Ins Owner Change1.27%
Market Cap169.20B
Analysts79.29
Price Target126.45 (29.89%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.1% |
Dividend Growth(5Y)13.67%
DP47.73%
Div Incr Years9
Div Non Decr Years9
Ex-Date04-13 2023-04-13 (0.51)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.86%
Min EPS beat(2)11.12%
Max EPS beat(2)20.6%
EPS beat(4)4
Avg EPS beat(4)18.56%
Min EPS beat(4)11.12%
Max EPS beat(4)25.59%
Revenue beat(2)2
Avg Revenue beat(2)4.93%
Min Revenue beat(2)3.37%
Max Revenue beat(2)6.5%
Revenue beat(4)4
Avg Revenue beat(4)6.27%
Min Revenue beat(4)3.37%
Max Revenue beat(4)8.01%
PT rev (1m)0.38%
PT rev (3m)5.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.9%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-0.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.52%
Revenue NY rev (1m)1.54%
Revenue NY rev (3m)1.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.23 | ||
| Fwd PE | 21.88 | ||
| P/S | 3.88 | ||
| P/FCF | 21.68 | ||
| P/OCF | 17.66 | ||
| P/B | 4.61 | ||
| P/tB | 49.29 | ||
| EV/EBITDA | 14.91 |
EPS(TTM)5.34
EY5.49%
EPS(NY)4.45
Fwd EY4.57%
FCF(TTM)4.49
FCFY4.61%
OCF(TTM)5.51
OCFY5.66%
SpS25.12
BVpS21.11
TBVpS1.98
PEG (NY)N/A
PEG (5Y)1.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.31% | ||
| ROE | 18.9% | ||
| ROIC | 12.19% | ||
| ROICexc | 14.73% | ||
| ROICexgc | 46.27% | ||
| OM | 19.41% | ||
| PM | 15.88% | ||
| GM | 56.15% |
ROICexgc(3y)41.26%
ROICexcg growth 3Y15.6%
ROICexcg growth 5Y30.11%
ROICexc(3y)12.59%
ROICexc growth 3Y26.6%
ROICexc growth 5Y40.77%
OM growth 3Y10.86%
OM growth 5Y23.9%
PM growth 3Y11.18%
PM growth 5Y55.6%
GM growth 3Y-1.36%
GM growth 5Y0.56%
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | 2.15 | ||
| Debt/EBITDA | 1.43 | ||
| Cap/Depr | 54.39% | ||
| Profit Quality | 112.56% | ||
| Current Ratio | 1.63 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | 4.46 |
F-Score6
WACC8.78%
ROIC/WACC5.27
Cap/Depr(3y)57.7%
Cap/Depr(5y)54%
Profit Quality(3y)120.74%
Profit Quality(5y)138.28%
Growth
EPS 1Y2.5%
EPS 3Y18.12%
EPS 5Y16.39%
EPS growth Q2Q-21.97%
EPS Next Y-16.68%
EPS Next 2Y-4.26%
EPS Next 3Y0.59%
EPS Next 5Y4.06%
Revenue growth 1Y1.34%
Revenue growth 3Y11.02%
Revenue growth 5Y9.77%
Revenue growth Q2Q-12.01%
Revenue Next Year-7.36%
Revenue Next 2Y-1.22%
Revenue Next 3Y1.28%
Revenue Next 5Y3.03%
EBIT growth 1Y-1.34%
EBIT growth 3Y23.08%
EBIT growth 5Y36.01%
EBIT Next Year-6.24%
EBIT Next 3Y3.93%
EBIT Next 5Y2.09%
FCF growth 1Y-9.76%
FCF growth 3Y20.16%
FCF growth 5Y11.97%
OCF growth 1Y-9.04%
OCF growth 3Y16.01%
OCF growth 5Y11.46%
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA